NO162238C - Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,4-dihydro-4-oksonaftyridinderivater. - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,4-dihydro-4-oksonaftyridinderivater.

Info

Publication number
NO162238C
NO162238C NO851643A NO851643A NO162238C NO 162238 C NO162238 C NO 162238C NO 851643 A NO851643 A NO 851643A NO 851643 A NO851643 A NO 851643A NO 162238 C NO162238 C NO 162238C
Authority
NO
Norway
Prior art keywords
oxonaftyridine
ingrediates
dihydro
preparation
therapeutic active
Prior art date
Application number
NO851643A
Other languages
English (en)
Norwegian (no)
Other versions
NO851643L (no
NO162238B (no
Inventor
Hirokazu Narita
Yoshinori Konishi
Hideyoshi Nagaki
Isao Kitayama
Yoriko Kabayashi
Mikako Shinagawa
Yasuo Watanabe
Akira Yotsuji
Shinzaburo Minami
Isamu Saikawa
Jun Nitta
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=13845280&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO162238(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of NO851643L publication Critical patent/NO851643L/no
Publication of NO162238B publication Critical patent/NO162238B/no
Publication of NO162238C publication Critical patent/NO162238C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NO851643A 1984-04-26 1985-04-24 Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,4-dihydro-4-oksonaftyridinderivater. NO162238C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59084963A JPS60228479A (ja) 1984-04-26 1984-04-26 １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩

Publications (3)

Publication Number Publication Date
NO851643L NO851643L (no) 1985-10-28
NO162238B NO162238B (no) 1989-08-21
NO162238C true NO162238C (no) 1989-12-06

Family

ID=13845280

Family Applications (1)

Application Number Title Priority Date Filing Date
NO851643A NO162238C (no) 1984-04-26 1985-04-24 Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,4-dihydro-4-oksonaftyridinderivater.

Country Status (30)

Country Link
JP (1) JPS60228479A (fr)
KR (1) KR870001693B1 (fr)
AR (1) AR241911A1 (fr)
AT (2) AT389698B (fr)
AU (2) AU565087B2 (fr)
BE (1) BE902279A (fr)
CH (1) CH673458A5 (fr)
CS (1) CS250684B2 (fr)
DD (1) DD238795A5 (fr)
DE (2) DE3514076A1 (fr)
DK (1) DK165877C (fr)
EG (1) EG17339A (fr)
ES (2) ES8700256A1 (fr)
FI (1) FI80453C (fr)
FR (2) FR2563521B1 (fr)
GB (2) GB2158825B (fr)
HU (2) HU194226B (fr)
ID (1) ID21142A (fr)
IL (1) IL75021A (fr)
IT (1) IT1209953B (fr)
LU (1) LU85871A1 (fr)
NL (2) NL187314C (fr)
NO (1) NO162238C (fr)
NZ (1) NZ211895A (fr)
PH (3) PH22801A (fr)
PL (1) PL147392B1 (fr)
PT (1) PT80349B (fr)
RO (2) RO91871B (fr)
SE (2) SE463102B (fr)
ZA (1) ZA853102B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6172753A (ja) * 1984-09-18 1986-04-14 Dainippon Pharmaceut Co Ltd ピリジルケトン誘導体
AU576657B2 (en) * 1985-01-23 1988-09-01 Toyama Chemical Co. Ltd. Naphthyridine and pyridine derivatives
AT392789B (de) * 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
DE3525108A1 (de) * 1985-06-07 1986-12-11 Bayer Ag, 5090 Leverkusen Antibakteriell wirksame chinoloncarbonsaeureester
IL79189A (en) * 1985-06-26 1990-07-12 Daiichi Seiyaku Co Quinoline and/or naphthyridine-4-oxo-3-carboxylic acid derivatives,process for their preparation and pharmaceutical compositions comprising them
US4962112A (en) * 1987-08-04 1990-10-09 Abbott Laboratories 7-(2-methyl-4-aminopyrrolidinyl)naphthryidine and quinoline compounds
IE62600B1 (en) * 1987-08-04 1995-02-22 Abbott Lab Naphtyridine antianaerobic compounds
US4859776A (en) * 1988-03-11 1989-08-22 Abbott Laboratories (S)-7-(3-aminopyrrolidin-1-yl)-1-(ortho, para-difluorophenyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid and method for its preparation
JP2844079B2 (ja) * 1988-05-23 1999-01-06 塩野義製薬株式会社 ピリドンカルボン酸系抗菌剤
DE3934082A1 (de) * 1989-10-12 1991-04-18 Bayer Ag Chinoloncarbonsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung als antivirale mittel
AU1161492A (en) * 1991-01-14 1992-08-17 Hanmi Pharmaceutical Co., Ltd. Novel quinolone compounds and processes for preparation thereof
FR2692577B1 (fr) * 1992-05-26 1996-02-02 Bouchara Sa Nouvelles quinolones fluorees, leur procede de preparation et les compositions pharmaceutiques en renfermant.
KR940014395A (ko) * 1992-12-09 1994-07-18 강박광 신규한 퀴놀론 유도체 및 그의 제조방법
KR0148277B1 (ko) * 1993-01-18 1998-11-02 채영복 신규한 플루오르퀴놀론계 유도체 및 그의 제조방법
WO1994025464A1 (fr) * 1993-04-24 1994-11-10 Korea Research Institute Of Chemical Technology Nouveaux derives d'acide quinolone-carboxylique et leur procede de preparation
KR950018003A (ko) * 1993-12-09 1995-07-22 스미스클라인 비참 피엘씨 신규한 퀴놀론 유도체 및 그의 제조 방법
WO1996012704A1 (fr) * 1994-10-20 1996-05-02 Wakunaga Seiyaku Kabushiki Kaisha Nouveau derive de pyridone-carboxylate, ou sel de celui-ci, et antibacterien le contenant comme principe actif
DK0897919T3 (da) 1996-04-19 2004-09-27 Wakunaga Pharma Co Ltd Nye pyridoncarboxylsyrederivater eller salte deraf samt antibakterielle midler indeholdende disse som den aktive bestanddel
CN1235605A (zh) * 1996-10-30 1999-11-17 拜尔公司 制备萘啶化合物的方法以及新的中间体
DE19713506A1 (de) 1997-04-01 1998-10-08 Bayer Ag Verfahren zur Herstellung von 2,6-Dichlor-5-fluornicotinonitril und die chemische Verbindung 3-Cyano-2-hydroxy-5-fluorpyrid-6-on-mononatriumsalz sowie dessen Tautomere
EP1161956A4 (fr) 1999-03-17 2005-03-16 Daiichi Seiyaku Co Compositions medicamenteuses
US6441182B1 (en) 1999-06-10 2002-08-27 Bayer Aktiengesellschaft Method for the production of 2,6-dichloro-5-fluoro-nicotinic acid and coarse and particularly pure 2,6-dichloro-5-fluoro-nicotinic acid
MXPA02002220A (es) 1999-09-02 2002-09-02 Wakunaga Pharma Co Ltd Derivados de acido quinolincarboxilico o su sal.
AU2001286852A1 (en) * 2000-08-29 2002-03-13 Chiron Corporation Quinoline antibacterial compounds and methods of use thereof
KR100981351B1 (ko) * 2003-10-29 2010-09-10 주식회사 엘지생명과학 7-클로로-1-사이클로프로필-6-플루오로-4-옥소-1,4-디하이드로-1,8-나프티리딘-3-카복실산의 제조방법
CN101792443A (zh) * 2010-03-09 2010-08-04 北京欧凯纳斯科技有限公司 氟代喹诺酮衍生物及其制备方法和用途
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
CN114369092A (zh) * 2021-12-20 2022-04-19 赤峰万泽药业股份有限公司 甲苯磺酸妥舒沙星及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2125310A1 (en) * 1971-05-21 1972-11-30 Sterling Drug Inc , New York, NY (V St A) 1-alkyl-1,4-dihydro-4-oxo-1,8-naphtyridine 3-carboxylic acids antibac
AR223983A1 (es) * 1978-08-25 1981-10-15 Dainippon Pharmaceutical Co Un procedimiento para-preparar derivados de acido 6-halogeno-4-oxo-7-(1-piperazinil)-1,8-naftiridin-3-carboxilico
DE3033157A1 (de) * 1980-09-03 1982-04-01 Bayer Ag, 5090 Leverkusen 7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-naphthyridin-3-carbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
US4382937A (en) * 1981-02-27 1983-05-10 Dainippon Pharmaceutical Co., Ltd. Naphthyridine derivatives and their use as anti-bacterials
IE55898B1 (en) * 1982-09-09 1991-02-14 Warner Lambert Co Antibacterial agents
IL74064A (en) * 1984-01-26 1988-09-30 Abbott Lab 1,7-disubstituted-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid derivatives and antibacterial compositions containing them
NZ210847A (en) * 1984-01-26 1988-02-29 Abbott Lab Naphthyridine and pyridopyrimidine derivatives and pharmaceutical compositions
AU576657B2 (en) * 1985-01-23 1988-09-01 Toyama Chemical Co. Ltd. Naphthyridine and pyridine derivatives
DE3525108A1 (de) * 1985-06-07 1986-12-11 Bayer Ag, 5090 Leverkusen Antibakteriell wirksame chinoloncarbonsaeureester

Also Published As

Publication number Publication date
RO95509A (fr) 1988-09-30
FR2563521A1 (fr) 1985-10-31
PL147392B1 (en) 1989-05-31
HU194226B (en) 1988-01-28
ATA122485A (de) 1989-06-15
ES542584A0 (es) 1986-09-16
HU197571B (en) 1989-04-28
NL8501172A (nl) 1985-11-18
ES551538A0 (es) 1987-07-01
PH25046A (en) 1991-01-28
DK185685D0 (da) 1985-04-25
DK165877B (da) 1993-02-01
NL187314C (nl) 1991-08-16
GB2158825A (en) 1985-11-20
PT80349A (en) 1985-05-01
IT1209953B (it) 1989-08-30
SE8804586D0 (sv) 1988-12-20
ES8706673A1 (es) 1987-07-01
GB2191776A (en) 1987-12-23
GB2158825B (en) 1989-01-25
AT389698B (de) 1990-01-10
SE8804586L (sv) 1988-12-20
NZ211895A (en) 1988-07-28
AU4165085A (en) 1985-10-31
ES8700256A1 (es) 1986-09-16
DE3546658C2 (fr) 1992-04-02
FR2614620A1 (fr) 1988-11-04
SE8502017D0 (sv) 1985-04-25
ID21142A (id) 1999-04-29
SE8502017L (sv) 1985-10-27
FR2563521B1 (fr) 1989-02-03
DE3514076C2 (fr) 1989-03-30
FR2614620B1 (fr) 1990-03-09
AU565087B2 (en) 1987-09-03
PH22801A (en) 1988-12-12
AU8180487A (en) 1988-03-24
KR850007596A (ko) 1985-12-07
GB8510297D0 (en) 1985-05-30
CH673458A5 (fr) 1990-03-15
IT8548002A0 (it) 1985-04-26
ATA267888A (de) 1989-09-15
CS250684B2 (en) 1987-05-14
DD238795A5 (de) 1986-09-03
PT80349B (pt) 1987-09-30
PH25228A (en) 1991-03-27
NO851643L (no) 1985-10-28
AU612993B2 (en) 1991-07-25
RO91871B (ro) 1987-07-31
FI80453B (fi) 1990-02-28
EG17339A (en) 1989-06-30
SE501412C2 (sv) 1995-02-13
GB8716897D0 (en) 1987-08-26
SE463102B (sv) 1990-10-08
RO91871A (fr) 1987-07-30
FI851637A0 (fi) 1985-04-25
AT390258B (de) 1990-04-10
GB2191776B (en) 1990-03-28
LU85871A1 (fr) 1985-12-16
NL9100648A (nl) 1991-08-01
NO162238B (no) 1989-08-21
JPS6320828B2 (fr) 1988-04-30
FI851637L (fi) 1985-10-27
DK185685A (da) 1985-10-27
JPS60228479A (ja) 1985-11-13
DK165877C (da) 1993-06-21
BE902279A (fr) 1985-10-25
AR241911A1 (es) 1993-01-29
ZA853102B (en) 1986-12-30
DE3514076A1 (de) 1985-10-31
KR870001693B1 (ko) 1987-09-24
IL75021A (en) 1994-01-25
HUT38634A (en) 1986-06-30
PL253108A1 (en) 1985-12-17
IL75021A0 (en) 1985-08-30
FI80453C (fi) 1990-06-11
RO95509B (ro) 1988-10-01

Similar Documents

Publication Publication Date Title
NO162238C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,4-dihydro-4-oksonaftyridinderivater.
NO166639C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte, basiske 2-aminotetraliner.
NO851949L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminotetralinderivater.
NO874869L (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
NO880182D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1, 2-dihydro-3h-indazol-3h-indazol-3-on-derivater.
NO902411D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-hydroksy-n-propylaminer.
NO166080C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5,6,8-trifluorkinoliner.
NO164168C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 1,7,4-triazolforbindelser.
NO863671D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetrahydro-2-heterocykloalkylpyrido(4,3)indoler.
NO166326C (no) Fremgangsmaate ved fremstilling av terapeutisk aktive 3,7-substituerte-8-oxo-5-thia-1-azabicyclo-(4,2,0)oct-2-en-2-carboxylater.
NO164654C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive (2-okso-1,2,3,5-tetrahydroimidazo (2,1-b)kinazolinyl)-oksylakylamider.
NO164897C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive oxazolidinonderivater.
NO873108D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,4-benzodiazepiner.
NO165069C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cyklopentyletere.
NO161177C (no) Analogifremgangsm te til fremstilling av terapeutisk aktive tioetere.
NO161313C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive fluorallylaminderivater.
NO165104C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 1, 1-disubstituerte cyklopropanderivater.
NO881768D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksaner.
NO862390D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,4-dihydropyridinderivater.
NO162072C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tienopyridinderivater.
NO168247C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-metoksy-alkyl-ammonium-tetrahydrofuraner.
NO854277L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 6-fenetylaminoalkyl-7-hydroksy-furo-(3,4-c)-pyridin-derivater.
NO166642C (no) Anaolgifremgangsmaate for fremstilling av terapeutisk aktive 3-aryl-5-alkylthio-4h-1,2,4-triazoler.
NO162468C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 12-amino-pyridazino (4[,5[;3,4)-pyrrolo-( 2,1-a)-isokinolinderivater.
NO865148D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive, substituerte benzamider.

Legal Events

Date Code Title Description
MK1K Patent expired